TY - JOUR
T1 - Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection
AU - Landaverde, Carmen
AU - Wells, Jennifer
AU - Hamner, Rebekah
AU - Goldstein, Janie L.
N1 - Publisher Copyright:
© 2016 Taylor & Francis.
PY - 2016/4/2
Y1 - 2016/4/2
N2 - The impact of chronic hepatitis C (HCV) worldwide is expected to increase as the population infected with HCV ages and more undiagnosed individuals are identified and linked to care through nation-wide initiatives. The development of interferon-free regimens involving the use of direct-acting antiviral agents, which disrupt key steps in viral replication, has revolutionized the treatment of chronic HCV infection. However, there remains a great medical need for HCV therapy that is of shorter duration, all-oral, with a high barrier to resistance, and highly effective for all patient populations including those with end-stage renal disease (ESRD) and cirrhosis. Grazoprevir, an HCV NS3/4A protease inhibitor and elbasvir, an NS5A inhibitor, have broad in vitro activity against most HCV genotypes and retain in vitro activity against many clinically relevant resistance-associated variants. The once daily regimen is well-tolerated and highly efficacious across wide-ranging patient populations including those with ESRD on hemodialysis.
AB - The impact of chronic hepatitis C (HCV) worldwide is expected to increase as the population infected with HCV ages and more undiagnosed individuals are identified and linked to care through nation-wide initiatives. The development of interferon-free regimens involving the use of direct-acting antiviral agents, which disrupt key steps in viral replication, has revolutionized the treatment of chronic HCV infection. However, there remains a great medical need for HCV therapy that is of shorter duration, all-oral, with a high barrier to resistance, and highly effective for all patient populations including those with end-stage renal disease (ESRD) and cirrhosis. Grazoprevir, an HCV NS3/4A protease inhibitor and elbasvir, an NS5A inhibitor, have broad in vitro activity against most HCV genotypes and retain in vitro activity against many clinically relevant resistance-associated variants. The once daily regimen is well-tolerated and highly efficacious across wide-ranging patient populations including those with ESRD on hemodialysis.
KW - Direct-acting antiviral agents
KW - Elbasvir
KW - Grazoprevir
KW - Hepatitis C
KW - Resistance-associated variants
UR - http://www.scopus.com/inward/record.url?scp=84959066049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959066049&partnerID=8YFLogxK
U2 - 10.1586/17474124.2016.1147346
DO - 10.1586/17474124.2016.1147346
M3 - Article
C2 - 26818134
AN - SCOPUS:84959066049
SN - 1747-4124
VL - 10
SP - 419
EP - 429
JO - Expert Review of Gastroenterology and Hepatology
JF - Expert Review of Gastroenterology and Hepatology
IS - 4
ER -